anti-PD-L1 CAR NK-cell therapy (TNK Therapeutics/NantKwest)

N/A

Report date: 2025/03/14 16:26:07

Base Information

Drug Nameanti-PD-L1 CAR NK-cell therapy (TNK Therapeutics/NantKwest)
Drug Alias NameCAR-TNK-based immunotherapies (Sorrento/Conkwest)anti-PD-L1 CAR-TNK-based immunotherapy (TNK Therapeutics/NantKwest)CAR-TNK-based immunotherapies (TNK Therapeutics/Conkwest)CAR-TNK-based immunotherapies (TNK Therapeutics/NantKwest)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed death-ligand 1 modulators
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunitybio IncTnk Therapeutics Inc
Inactive CompaniesSorrento Therapeutics Inc
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A